

# Human HSD17B13 ELISA Kit

## Catalog No. EA200008

### Principle of the Assay

17 $\beta$ -Hydroxysteroid dehydrogenase type 13 (HSD17B13) is an enzyme that is encoded by the *HSD17B13* gene in humans. HSD17B13 is a 300-amino-acid protein that is localized on lipid droplet. The RNA expression of *HSD17B13* is highly restricted to the liver, specifically in hepatocytes but not other cell types in the liver. HSD17B13 is involved in various metabolic processes, including steroid hormones, fatty acids, cholesterol, and bile acids. HSD17B13 has been reported to catalyze multiple substrates including steroids, bioactive lipids including leukotriene B4 and 12(R)-hydroxyeicosatetraenoic acid, and retinol. HSD17B13 enzymatic activity attributes to hepatic cell injury, inflammation, and fibrosis, chronically leading to the development of alcoholic liver disease (ALD), nonalcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma (HCC). HSD17B13 expression is significantly upregulated in patients and mice with non-alcoholic fatty liver disease (NAFLD). Hepatic overexpression of HSD17B13 promotes lipid accumulation in the liver. HSD17B13 has potential as a biomarker of advanced liver disease, such as non-alcoholic steatohepatitis (NASH) and liver cancer.

This sandwich ELISA is used to measure human HSD17B13 in tissue homogenates, cell lysates, serum, plasma and other biological fluid samples. Microtitration wells coated with anti-human HSD17B13 capture antibody are exposed to test specimens. The HSD17B13 antigen in the specimen is specifically captured onto the immobilized antibody during specimen incubation. The captured HSD17B13 antigen is then reacted with a biotinylated human HSD17B13 detection antibody. Subsequently, Streptavidin-HRP conjugate is then added. After wash, specifically bound enzyme conjugate is detected by reaction with the Substrate Solution, tetramethylbenzidine (TMB). The assay is measured spectrophotometrically to indicate the level of HSD17B13 present in a sample.

### Kit Presentation

#### Materials Supplied

The reagents supplied in this pack are for Research Use Only.

Description	Quantity
HSD17B13 Antibody Coated 96-well Plate in foil pouch with desiccant	1
Recombinant human HSD17B13 Standard (1000ng/mL)	0.1 mL
Biotinylated HSD17B13 Detection Antibody (100x)	120 $\mu$ L
Streptavidin Conjugated Horseradish Peroxidase (100x)	120 $\mu$ L
Assay Buffer	60 mL
Detection Antibody Diluent	12 mL
Substrate Solution (TMB)	12 mL
Stop Solution (1N HCl)	12 mL
Wash Buffer (20x)	60 mL
Plate Sealer	3

#### Additional Requirements for Manual Processing

- Horizontal orbital plate shaker capable of maintaining a speed of 450 $\pm$ 50 rpm.
- Disposable tip micropipettes to deliver volumes of 5 $\mu$ L, 10  $\mu$ L, 25  $\mu$ L, 100  $\mu$ L and 200  $\mu$ L (multichannel pipette preferred for dispensing reagents into microtiter plates).
- Distilled or deionized water.
- Clean, disposable plastic/glass test tubes, approximate capacities 5mL and 10mL.
- Range of standard, clean volumetric laboratory glassware consisting of, at least, 15 mL and 100 mL beakers, 1 L graduated cylinder, 1 mL, 5 mL, and 10 mL pipettes.
- Absorbent paper towels.
- Automatic microplate washer or laboratory wash bottle.
- Microplate reader with 450nm filter.
- Latex gloves, safety glasses and other appropriate protective garments.
- Biohazard waste containers.
- Safety pipetting devices for 1 mL or larger pipettes.
- Timer.

### Storage and Stability

All reagents should be stored at 2-8°C and should not be used beyond the expiration date on the label. Once opened, microtitration strips may be stored at 2-8°C until the expiration date on the label, provided that desiccated conditions are maintained. Unused strips should be returned to their original foil pouch along with the sachet of desiccant. Secure open foil pouch using zip top before storage. The working strength Wash Buffer should not be stored for longer than 3 weeks at 2-8°C. It is recommended that Wash buffer be freshly diluted before each assay. If the working strength buffer becomes visibly cloudy or develops precipitate during the 3 weeks, do not use it.

### Indications of Deterioration

The human HSD17B13 Assay kit may be considered to have deteriorated if:

- Reagents becoming visibly cloudy or develop precipitate. Note: Concentrated Wash buffer, when cold, normally develops crystalline precipitates, which re-dissolve on heating at 37°C.
- The Substrate Solution turns dark blue. This is likely to be caused by chemical contamination of the Substrate Solution.

### Warnings and Precaution

#### Safety

- The reagents supplied in this kit are for **Research use only**.
- Caution: All blood products should be treated as potentially infectious.

Essential precautions can be summarized as follows:

>do not pipette by mouth.

>Wear disposable gloves during all specimen and assay manipulations.

>Avoid use of sharp or pointed liquid handling devices, which may puncture skin.

>Do not smoke, eat or drink in the laboratory work area.

>Avoid splashing of liquid specimens and reagents and the formation of aerosols.

>Wash hands thoroughly on completion of a manipulation.

>The Centers for Disease Control & Prevention and the National Institutes of Health recommend that potentially infectious agents be handled at Biosafety Level 2.

3. The kit contains reagent systems which are optimized and balanced for each kit lot. Do not interchange reagents from kits with different lot numbers. Do not interchange vial caps or stoppers either within or between kits.

4. The Substrate Solution and Stop Solution in this kit contain ingredients that can irritate the skin and cause eye damage. Handle them with care and wear suitable protective clothing and eye/face protection. In case of contact with skin or eyes, immediately flush the affected area with plenty of water. For eyes, obtain medical attention.

5. Disposal or decontamination of fluid in the waste reservoir from either the plate washer or trap for vacuum line in the manual system should be in accordance with guidelines set forth in the Department of Labor, Occupational Safety and Health Administration, occupational exposure to blood-borne pathogens; final rule (29 CFR 1910.1030) FEDERAL REGISTER, pp. 64176-84177, 12/6/91.

#### **Technical Suggestions**

1. This kit should be used in strict accordance with the instructions in the Package Insert.
2. Do not use the kit after the expiration date printed on the outer carton label.
3. Do not cross contaminate reagents.
4. To ensure accurate results and avoid cross-contamination, use proper adhesive plate sealers during incubation steps, and change pipette tips when adding each standard and sample. Multi-channel pipettes are recommended for large assays. Always use fresh pipette tips when drawing from stock reagent bottles.
5. All reagents should be added to the plate in the same order.
6. Protect Substrate Solution from light.
7. If the Stop Solution does not mix thoroughly with the Substrate Solution, the color in the wells may appear green after adding stop solution. Gently tap the plate or pipette up and down to mix until the color in the wells change to yellow (avoid bubbles during this step).
8. Always use clean, preferably disposable, glassware for all reagent preparation.
9. Allow foil bags to warm to room temperature before opening. This avoids condensation on the inner surface of the bag, which may contribute to a deterioration of coated strips intended for future use.
10. Reagents should be dispensed with the tip of the micropipettes touching the side of the well at a point about mid-section. Follow manufacturer's recommendations for automatic processors.
11. Always keep the upper surface of the microtitration strips free from excess fluid droplets. Reagents and buffer over-spill should be blotted dry on completion of the manipulation.
12. Do not allow the wells to completely dry during an assay.
13. Automatic or semi-automatic EIA processors or liquid handling systems should be qualified specifically for use with the assay by demonstration of equivalence to the manual processing methods.
14. Consistent with good laboratory practice, it is recommended that all pipetting devices (manual or automatic), timers and thermometers are regularly calibrated according to the manufacturer's instructions.
15. Care must be taken to ensure that specimens are dispensed correctly to each test well. If a specimen is inadvertently not added to a well, the result for that well

will be non-reactive, regardless of the actual result of the specimen.

#### **Method of Use**

##### *Specimen Collection and Storage*

The Human HSD17B13 ELISA is intended for use with cell lysates, serum, and plasma. The specimen should be tested as soon as possible. However, if the specimen needs storage, the specimens should be stored frozen at -20°C or below. Do not use self-defrosting freezers. Specimens that have been frozen and thawed should be thoroughly mixed before testing.

Tissue Homogenates - Rinse 100 mg of tissue with 1X PBS, then homogenize in 1 mL of 1X PBS and store overnight at -20°C. Perform two freeze-thaw cycles to break the cell membranes, then centrifuge the homogenate for 5 minutes at 5,000 x g, 2-8°C. Remove the supernatant and assay immediately. Alternatively, aliquot and store samples at -20°C or -80°C. Centrifuge the sample again after thawing before the assay. Avoid repeated freeze-thaw cycles.

Cell Lysates - Adherent cells should be detached with trypsin and then collected by centrifugation (suspension cells can be collected by centrifugation directly). Wash cells three times in cold PBS. Resuspend cells in PBS (1x) and ultrasonicate the cells 4 times (or freeze cells at ≤ -20°C. Thaw cells with gentle mixing. Repeat the freeze/thaw cycle 3 times.) Centrifuge at 1,500 x g for 10 minutes at 2 - 8°C to remove cellular debris.

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using heparin or EDTA as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Cell culture supernatants and other biological fluids - Remove particulates by centrifugation and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

##### *Rinse Cycle*

Efficient rinsing to remove un-complexed components is a fundamental requirement of enzyme immunoassay procedures. Automatic plate washers may be used provided they meet the following criteria: 1. All wells are completely aspirated. 2. All wells are filled to the rim (300 µL) during the rinse cycle. 3. Wash buffer is dispensed at a good flow rate. 4. The microtitration plate washer must be well maintained to prevent contamination from previous use. Manufacturer's cleaning procedures must be followed diligently

For the rinse cycle, the machine should be set to three washes for the first two rinse cycles and five washes for final rinse cycle. On completion of the cycle, invert the microtitration plate and tap firmly on absorbent paper towels. Check for any residual Wash buffer in the wells and blot dry the upper surface of the wells with a paper towel.

*Alternatively, the following manual system may be employed:*

1. Discard or aspirate well contents using a vacuum line fitted with a trap.
2. Fill all wells to the brim with wash buffer dispensed from a squeeze-type laboratory wash bottle.

3. Discard or aspirate fluids.
4. Repeat steps 2 and 3, two times (Repeat steps 2 and 3 four times in final wash cycle).
5. Invert the microtitration plate and tap firmly on absorbent paper towels.

#### Preparation for the Assay

1. **Standard preparation:** Prepare protein standard by diluting 10 $\mu$ L of standard stock into 490  $\mu$ L (1:50 dilution) of assay buffer. This will give a final concentration of 20 ng/mL as shown in Table 1.
2. **Sample preparation:** Sample concentrations should be predicted before being used in the assay. For normal human serum or plasma, use neat samples for the test. For tissue homogenate, cell lysate samples and samples with unknown HSD17B13 concentration, HSD17B13 concentration must be estimated prior to performing the full experiment by testing a serially diluted representative sample. Select an optimal dilution level such that the final target protein concentration falls near the middle of the assay linear dynamic range. Proper dilution using Assay Buffer is needed for samples with HSD17B13 concentration beyond the highest detection range. If samples need more than 500-fold dilution, dilute sample with PBS buffer first, then dilute sample with Assay Buffer in the final dilution step.
3. **Detection antibody preparation:** Dilute the concentrated biotin conjugated detection antibody 1:100 using Detection Antibody Diluent.
4. **SA-HRP preparation:** Dilute the concentrated streptavidin HRP conjugate 1:100 using Assay Buffer.
5. **Wash Buffer:** Prepare working-strength Wash buffer by diluting 1 part concentrate with 19 parts of distilled or de-ionized water. If a kit is likely to be utilized over a period in excess of 4 weeks, then it is recommended that only enough stock concentrate be diluted sufficient for immediate needs.

#### Quantitative Assay Procedure

To test quantitatively, a standard curve should be prepared using assay diluent as shown in the table below. Each standard should be run in duplicate.

**Table 1: Human HSD17B13 Quantitative Standard Curve Generation**

Standard Number	Concentration of HSD17B13 (ng/mL)	HSD17B13 Standard ( $\mu$ L)	Assay Buffer ( $\mu$ L)
1	20	10	490
2	10	250 of #1	250
3	5	250 of #2	250
4	2.5	250 of #3	250
5	1.25	250 of #4	250
6	0.625	250 of #5	250
7	0.3125	250 of #6	250
8	0		250

#### Assay Procedure

1. Allow all reagents to reach room temperature (18-25°C).
2. Select sufficient microtitration well strips to accommodate all test specimens, controls and reagent blank. Fit the strips into the holding frame. Label wells according to specimen identity using the letter/number cross-reference system molded into the plastic frame.
3. Dispense 100  $\mu$ L of each standard and sample into appropriate wells. Note: All standards and samples should be tested in duplicate. Note: Depending on the HSD17B13 concentration of your sample, dilution using Assay Buffer may be needed. If the sample HSD17B13 concentration is not known, you can titrate the original sample.
4. Incubate for 2 hours at room temperature with moderate shaking (450 $\pm$ 50rpm) on a horizontal orbital plate shaker.
5. Wash the microtitration plate 3 times as described in the Rinse Cycle section.
6. Pipette 100  $\mu$ L of working concentration detection antibody into each well and incubate for 1.5 hours at room temperature with moderate shaking (450 $\pm$ 50rpm) on a horizontal orbital plate shaker.
7. Wash the microtitration plate 3 times as described in the Rinse Cycle section.
8. Pipette 100  $\mu$ L of working concentration Streptavidin HRP conjugate into each well and incubate for 25 minutes at room temperature with moderate shaking (450 $\pm$ 50rpm) on a horizontal orbital plate shaker.
11. Wash the microtitration plate 5 times as described in the Rinse Cycle section.
12. Dispense 100  $\mu$ L Substrate Solution into each well. A multichannel pipette should be used for best results. Leave at room temperature (18-25°C) and protected from direct sunlight for 20-25 minutes.
13. Stop the reaction by adding 100  $\mu$ L of Stop Solution to each well. The blue solution should change to a uniform yellow color. Ensure that the undersides of the wells are dry and that there are no air bubbles in the well contents.
14. Immediately after adding the Stop solution, read the absorbance values at 450 nm using a microtitration plate reader.

#### Interpretation of Results

##### Quantitative Analysis

Average the duplicate readings for each standard and sample, and subtract the average zero standard optical density (O.D.).


A 4-parameter logistic (4-PL) or a linear regression model providing a point-to-point curve fitting provides acceptable results. Create a standard curve by reducing the data using computer software capable of generating a four-parameter logistic (4-PL) or a linear regression curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. Do not force the line to be linear. The concentration of the samples can be found directly from the standard curve.

**Table 2. Example Data at 450nm.**

Standards	450 nm absorbance
Standard 1 (20 ng/mL)	2.2681
Standard 2 (10 ng/mL)	1.2576
Standard 3 (5 ng/mL)	0.7133
Standard 4 (2.5 ng/mL)	0.4104
Standard 5 (1.25 ng/mL)	0.2446
Standard 6 (0.625 ng/mL)	0.1639
Standard 7 (0.3125 ng/mL)	0.1227
Standard 8 (0 ng/mL)	0.0867

**Typical Human HSD17B13 ELISA Kit Standard Curve**

This standard curve was generated at OriGene for demonstration purpose only. A standard curve must be run with each assay.



Note: This standard curve is only an example and should not be used to generate any results.

**Performance Characteristics**

**1. Recovery**

The recovery of human HSD17B13 spiked to three different-levels of the assay range in diluted samples was evaluated.

Sample Type	Average % Recovery
Serum	104%
EDTA-plasma	102%
Heparin-plasma	112%
Cell culture media	104%

**2. Linearity**

To assess the linearity of the assay, neat or human HSD17B13 spiked samples were diluted to produce samples with values within the dynamic range of the assay.

		Culture media	Heparin-plasma	EDTA-plasma	Serum
1:2	%Expected	95.02	104.39	101.87	104.17
1:4	%Expected	96.15	103.37	97.54	103.72
1:8	%Expected	87.16	94.08	83.87	93.90

**3. Sensitivity: 0.1ng/mL**

**4. Precision**

Human serum, plasma and culture media samples with different levels of HSD17B13 were assayed 10 times each on three different assays. The intra-assay CV percentage and inter-assay CV percentage were calculated.

Sample	%CV in Assay 1	%CV in Assay 2	%CV in Assay 3	Ave %CV
Spiked Serum (n=10)	3.73	5.05	6.73	5.17
Spiked EDTA-Plasma (n=10)	6.35	5.35	7.31	6.34
Spiked Heparin-Plasma (n=10)	4.95	6.62	9.33	6.97
Spiked Culture Media (n=10)	8.47	9.54	9.50	9.17

Sample	Mean (pg/ml) in assay1	Mean (pg/ml) in assay2	Mean (pg/ml) in assay3	Ave (pg/ml)	SD	%CV
Spiked Serum (n=10)	0.90	0.85	0.90	0.88	0.03	2.97
Spiked EDTA-Plasma (n=10)	0.85	0.83	0.82	0.84	0.02	2.03
Spiked Heparin-Plasma (n=10)	0.62	0.55	0.60	0.59	0.04	5.91
Spiked Culture Media (n=10)	0.93	0.81	0.90	0.88	0.06	6.72

**Limitations of Use**

1. Assay values determined using assays from different manufacturers or different methods may not be used interchangeably.
2. The assay cannot be used to quantitate samples with HSD17B13 assay values greater than the highest standard without further serial dilution of the samples.

**Contact Information:**

**OriGene Technologies, Inc**  
9620 Medical Center Drive  
Rockville, MD 20850  
Tel: 888.267.4436  
Fax: 301.340.9254  
Web: www.origene.com

Version 01042024

## Assay Flowchart

